For people who can’t take statins because of muscle pain, evolocumab alone cuts bad cholesterol by over half and helps many reach safe levels, while another drug (ezetimibe) doesn’t work nearly as well.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Establish causal superiority of evolocumab over ezetimibe in statin-intolerant patients.
A double-blind RCT of 500 statin-intolerant adults with ASCVD, randomized to evolocumab 140 mg Q2W vs ezetimibe 10 mg daily, with LDL-C change at 24 weeks as primary endpoint and blinded adjudication of muscle symptoms.
Provide the most precise estimate of evolocumab’s efficacy in statin intolerance by pooling all relevant trials.
A systematic review of all RCTs comparing PCSK9 inhibitors to placebo or ezetimibe in statin-intolerant patients, pooling LDL-C reduction and target attainment, with sensitivity analysis for intolerance definition.
Confirm real-world effectiveness and persistence in statin-intolerant patients.
A prospective cohort of 5,000 statin-intolerant patients prescribed evolocumab vs ezetimibe, tracking LDL-C, adherence, and MACE over 3 years, with adjustment for baseline risk.